CVRx, Inc. (CVRX)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.05+1.33%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CVRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue expanding U.S. sales territories, active implanting centers, and physician/patient awareness to grow Barostim revenue.
Stated as a priority in 2 of last 2 quarters. U.S. revenue grew 22% from $11.23 million in 2025-Q1 to $13.7 million in 2026-Q1, supported by an increase in active implanting centers from 252 to 257. Management's statements and financials show delivering progress on U.S. market expansion.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“U.S. revenue for Q1 2026 was $13.7 million, a 22% increase over prior year quarter.”
“Active implanting centers in the U.S. grew to 257 as of March 31, 2026, compared to 252 as of December 31, 2025.”
Sustain gross margin expansion through operational efficiencies and product mix improvements.
Stated in 3 of last 3 quarters. Gross margin improved from 84% in 2025-Q1 to 87% in 2026-Q1, with full year 2026 guidance raised to 86%-87%. Management is delivering on gross margin improvement as reflected in financial results and updated guidance.
“Gross margin guidance updated to between 86% and 87% for full year 2026.”
“Gross margin for Q1 2026 was 87%, compared to 84% in Q1 2025.”
“Gross margin guidance for 2026 initially set between 84% and 86%.”
Manage operating expenses to stay within the guided range of approximately $99M to $107M annually.
Stated in 3 of last 3 quarters. Operating expenses guidance for 2026 was revised down from $103M-$107M to $99M-$101M. Actual operating expenses were $25.0M in 2026-Q1, slightly higher than $23.7M in 2025-Q1. Management shows mixed progress controlling expenses within guidance.
“Operating expenses guidance revised to $99.0 million to $101.0 million for full year 2026.”
“Operating expenses guidance was $103.0 million to $107.0 million for full year 2026.”
“Operating expenses guidance for 2026 initially set between $103.0 million and $107.0 million.”
Progress enrollment and data collection in BENEFIT-HF trial to expand Barostim indication and patient access.
Stated in 2 of last 2 quarters. The first site activation and patient enrollment occurred in 2026-Q1 as planned. Management continues to emphasize the trial's potential to expand the patient population approximately threefold. Progress is delivering initial milestones.
“First site activated and first patient enrolled in BENEFIT-HF clinical trial.”
“BENEFIT-HF trial described as landmark randomized controlled trial to expand Barostim indication.”
Improve reimbursement rates and prior authorization approval for Barostim, focusing on Medicare Advantage plans.
Stated in 2 of last 2 quarters. The 30-day approval rate for Medicare Advantage prior authorizations improved from 31% in 2024 to 50% in early 2026, reflecting progress in reimbursement coverage expansion. Management is delivering measurable improvement in this area.
“Early data shows 30-day approval rate for Medicare Advantage prior authorizations increased to 50%.”
“Approval rate increased from 31% in 2024 to 44% in 2025.”
Over the trailing year it converted 0.75x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.